|
More info... Biosignal announced that it will exclusively license the worldwide rights in wound and hospital hygiene anti-bacterial products to a second United States spin-out company to be led by entrepreneur Paul Hawken who will establish the new entity in the US and will be executive chair and CEO. He has agreed to performance criteria for the new company including $US 2 million to be raised within 12 ... |
|
Read more... [Biosignal to Commercialise Anti-bacterial Wound and Hospital Hygiene Products (BPT.AX, 00821649, 200]
|